Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 02, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of March 31, 2007, in conformity with Disclosure and Transparency Rules 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital: 6,010,402,644 Ordinary shares of 25p each.
- Treasury Shares: 281,382,678 Ordinary shares held in Treasury.
- Total Voting Rights: 5,729,019,966.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance or operational metrics. The document only states the current capital structure as of the reporting date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital figures intended for shareholder calculations under Financial Services Authority rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,729,019,966) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (281,382,678) to calculate the effective float.
- Check subsequent filings for financial performance data, as this 6-K contains no financial results.